Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$155.55M$155.55Mderived+12.1% vs Q4 2022 Net Income-$14.33M-$14.33MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$67,588,000+18.9% Operating Incomederived-$18,574,000N/M Operating Cash Flowderived$17,784,000N/M Free Cash Flowderived$10,727,000N/M Margins · derivedGross margin43.5%+2.5 pt vs Q4 2022
Operating margin-11.9%+7.1 pt vs Q4 2022
Net margin-9.2%+7.1 pt vs Q4 2022
ended Dec 31, 2023 · filed Feb 20, 2024 · 51 d after period end